Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APMNASDAQ:DRRXNASDAQ:MTEXNASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$0.88+2.8%$0.89$0.46▼$7.49$4.70M-0.16612,644 shs11,473 shsDRRXDURECT$0.58-1.2%$0.75$0.52▼$1.88$18.07M0.6657,147 shs41,243 shsMTEXMannatech$10.16+0.5%$9.85$6.75▼$16.49$19.31M1.064,390 shs660 shsSNYRSynergy CHC Corp. (Uplisting)$1.81-3.7%$2.59$0.12▼$10.00$16.45MN/A794,572 shs31,244 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group+2.79%-6.39%+23.80%-27.36%-82.97%DRRXDURECT-1.19%-3.00%-27.24%-26.24%-51.50%MTEXMannatech+6.95%-2.78%+21.39%-13.83%+33.16%SNYRSynergy CHC Corp. (Uplisting)-3.72%-7.18%-10.84%-54.75%+180,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPMAptorum Group0.9444 of 5 stars0.03.00.00.02.71.70.6DRRXDURECT0.3498 of 5 stars0.02.00.04.40.00.00.0MTEXMannatech0.8221 of 5 stars0.05.00.80.00.61.70.0SNYRSynergy CHC Corp. (Uplisting)2.5683 of 5 stars3.80.00.00.00.61.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 0.00N/AN/AN/ADRRXDURECT 2.00HoldN/AN/AMTEXMannatech 0.00N/AN/AN/ASNYRSynergy CHC Corp. (Uplisting) 3.50Strong Buy$10.00452.49% UpsideCurrent Analyst Ratings BreakdownLatest APM, DRRX, MTEX, and SNYR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025DRRXDURECTHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K10.93N/AN/A$2.97 per share0.30DRRXDURECT$2.03M8.90N/AN/A$0.50 per share1.16MTEXMannatech$117.87M0.16N/AN/A$5.64 per share1.80SNYRSynergy CHC Corp. (Uplisting)$34.83M0.45N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$2.83MN/A0.00∞N/AN/AN/AN/AN/ADRRXDURECT-$27.62M-$0.27N/AN/AN/A-198.58%-300.62%-65.17%5/12/2025 (Estimated)MTEXMannatech-$2.24M$1.33N/A∞N/A-1.26%-15.62%-3.76%5/13/2025 (Estimated)SNYRSynergy CHC Corp. (Uplisting)N/AN/A0.003.07N/AN/AN/AN/AN/ALatest APM, DRRX, MTEX, and SNYR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025DRRXDURECT-$0.14N/AN/AN/A$0.29 millionN/A3/31/2025Q4 2024SNYRSynergy CHC Corp. (Uplisting)$0.10$0.01-$0.09$0.01$10.55 million$10.30 million3/26/2025Q4 2024DRRXDURECT$0.06-$0.06-$0.12$0.24$6.91 million$2.30 million3/26/2025Q4 2024MTEXMannatechN/A$1.20N/A$1.20N/A$29.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/ADRRXDURECTN/AN/AN/AN/AN/AMTEXMannatech$0.201.97%N/A15.04%N/ASNYRSynergy CHC Corp. (Uplisting)N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum Group0.241.16N/ADRRXDURECTN/A0.710.60MTEXMannatech0.441.250.74SNYRSynergy CHC Corp. (Uplisting)N/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%DRRXDURECT28.03%MTEXMannatech12.98%SNYRSynergy CHC Corp. (Uplisting)N/AInsider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%DRRXDURECT3.20%MTEXMannatech41.50%SNYRSynergy CHC Corp. (Uplisting)N/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group305.35 million1.87 millionNot OptionableDRRXDURECT8031.04 million30.05 millionOptionableMTEXMannatech2501.90 million1.10 millionNot OptionableSNYRSynergy CHC Corp. (Uplisting)408.75 millionN/AN/AAPM, DRRX, MTEX, and SNYR HeadlinesRecent News About These CompaniesSynergy CHC Corp. Announces First Quarter 2025 Earnings and Conference Call InformationMay 1, 2025 | globenewswire.comSynergy CHC Stock Short Interest Report | NASDAQ:SNYR | BenzingaApril 17, 2025 | benzinga.comSynergy CHC Reports its Eighth Consecutive Quarter of Profitability and its Fourth Quarter and Full Year 2024 Financial ResultsMarch 31, 2025 | markets.businessinsider.comSynergy CHC Corp. Announces Fourth Quarter and Full Year 2024 Earnings and Conference Call InformationMarch 21, 2025 | markets.businessinsider.comRoth MKM Initiates Coverage of Synergy CHC (SNYR) with Buy RecommendationJanuary 22, 2025 | msn.comSynergy CHC Announces 7th Quarter of ProfitabilityDecember 7, 2024 | markets.businessinsider.comSynergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Purchases $2,700,000.00 in StockOctober 25, 2024 | insidertrades.comSynergy CHC Corp. Announces Closing of Initial Public OfferingOctober 24, 2024 | globenewswire.comSynergy CHC Corp. Prices $10.35 Million Initial Public OfferingOctober 22, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPM, DRRX, MTEX, and SNYR Company DescriptionsAptorum Group NASDAQ:APM$0.88 +0.02 (+2.79%) Closing price 05/7/2025 03:46 PM EasternExtended Trading$0.89 +0.01 (+1.25%) As of 05/7/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.DURECT NASDAQ:DRRX$0.58 -0.01 (-1.19%) As of 05/7/2025 04:00 PM EasternDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Mannatech NASDAQ:MTEX$10.16 +0.05 (+0.49%) Closing price 05/7/2025 03:50 PM EasternExtended Trading$10.16 0.00 (0.00%) As of 05/7/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.Synergy CHC Corp. (Uplisting) NASDAQ:SNYR$1.81 -0.07 (-3.72%) As of 05/7/2025 03:34 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
